Latest Breaking News On - United kingdom general practice research - Page 1 : comparemela.com

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 —— NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy — .

United kingdomHong kongWeiguo suStock exchange of hong kongExchange commissionPractice research databaseChina limitedChina national medical products administrationPriority reviewBreakthrough therapyFlorham parkNew drug applicationExecutive directorChief executive officerChief scientific officerLancet haematology

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomHong kongZhou yiBen atwell alex shawWeiguo suExchange commissionChina limitedPractice research databaseChina national medical products administrationStock exchange of hong kongPriority reviewBreakthrough therapyNew drug applicationExecutive directorChief executive officerChief scientific officer

Should I vaccinate my children? - Health - Life & Style

Should I vaccinate my children? - Health - Life & Style
ahram.org.eg - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ahram.org.eg Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesWorld health organizationAl qahirahAndrew wakefieldEcole polytechniquePractice research databaseHarvard universityUniversity of oxfordWorld healthReviews immunologyUnited kingdom general practice researchEngland journalChild psychologyInfectious diseasesDisease control

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints Overall safety consistent with sovleplenib known profile .

United statesHong kongUnited kingdomBen atwell alex shawMichael shiZhou yiRen chi yangAnnie chengMark leePractice research databaseNational medical products administration of chinaHuazhong university of scienceAmerican society of hematologyChinese academy of medical sciencesSteering committeeInstitute of hematology

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01

Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints Overall safety consistent with.

Hong kongUnited kingdomUnited statesBen atwell alex shawZhou yiMark leeRen chi yangMichael shiAnnie chengHuazhong university of scienceNational medical products administration of chinaPractice research databaseAmerican society of hematologySteering committeeChinese academy of medical sciencesInstitute of hematology